Diatech Acquires SensoQuest, Launches New Thermal Cycler
The Italian diagnostics firm enters the instrumentation market with a high-precision 384-well thermal cycler.
Updated on Oct. 26, 2026 in Biotech
Italian molecular diagnostics company Diatech Pharmacogenetics has acquired Germany-based SensoQuest. Simultaneously, the company launched the Labcycler, a PCR thermal cycler manufactured in Jesi, Italy, designed for high-throughput laboratory applications.
Why it matters
The acquisition marks Diatech Pharmacogenetics' formal expansion into hardware manufacturing, moving the company from a diagnostics-focused model into the laboratory instrumentation sector.
The Labcycler features an electroformed, gold-plated silver block capable of supporting 96-well and 384-well applications. It is rated for a lifespan of approximately 20 years or 600,000 thermal cycles.
The players
Diatech Pharmacogenetics
An Italian molecular diagnostics firm that is expanding its portfolio into laboratory instrumentation.
SensoQuest
A Germany-based developer of laboratory equipment now acquired by Diatech.
The details
The device uses independently controlled Peltier elements—semiconductor devices that create temperature differences when an electric current is applied—to achieve its thermal accuracy. A quick-change system allows operators to swap thermocycler blocks in seconds to transition between different plate formats.
Timeline
October 26, 2026: Diatech Pharmacogenetics announced the acquisition and product launch.
The Tech Race
The acquisition follows a trend of diagnostic companies bringing PCR thermal cycler hardware production in-house to capture more of the laboratory workflow. Diatech now competes directly in the specialized instrument market where high-throughput reliability is the primary performance metric.
Clinical laboratories requiring high-precision thermal cycling for 96-well or 384-well assays can now source equipment directly from the integrated entity. The system is designed for long-term use with a durability rating of 20 years.
The takeaway
This acquisition signals that Diatech is prioritizing vertical integration to control its instrument supply chain. Industry analysts should watch for further hardware-focused acquisitions as the company seeks to scale its newly established instrumentation division.
Further reading
For more on the latest instrumentation in clinical diagnostics, visit the Biotech section.
Source note: This article includes information reported by Manufacturingchemist.
